Teva Pharmaceutical Industries (FRA:TEV) Cyclically Adjusted Revenue per Share: €17.53 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TEV Teva Pharmaceutical Industries Ltd FRA:TEV
56 GF Score
Price €30.00
GF Value €17.50
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Cyclically Adjusted Revenue per Share?

Teva Pharmaceutical Industries FRA:TEV -1.64% 56 Cyclically Adjusted Revenue per Share is €17.53 as of Jun. 2026. GuruFocus rates FRA:TEV with a GF Score™ of 56/100 and a GF Value™ of €17.50 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Teva Pharmaceutical Industries's adjusted revenue per share for the three months ended in Jun. 2026 was €3.086. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €17.53 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Teva Pharmaceutical Industries's average Cyclically Adjusted Revenue Growth Rate was -4.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -4.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -2.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Teva Pharmaceutical Industries was 19.10% per year. The lowest was -4.70% per year. And the median was 15.40% per year.

As of today (2026-08-01), Teva Pharmaceutical Industries's current stock price is €30.00. Teva Pharmaceutical Industries's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €17.53. Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio of today is 1.71.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Teva Pharmaceutical Industries was 3.39. The lowest was 0.31. And the median was 0.75.


Teva Pharmaceutical Industries  (FRA:TEV) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=30.00/17.53
=1.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Teva Pharmaceutical Industries was 3.39. The lowest was 0.31. And the median was 0.75.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Teva Pharmaceutical Industries Cyclically Adjusted Revenue per Share Related Terms


Teva Pharmaceutical Industries Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Cyclically Adjusted Revenue per Share Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.38 18.13 16.07 16.83 15.82

Teva Pharmaceutical Industries Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.62 15.67 15.82 16.29 17.53

FRA:TEV vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio falls into.


FRA:TEV
56GF Score
Teva Pharmaceutical Industries Ltd FRA:TEV
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Teva Pharmaceutical Industries's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.086/333.9520*333.9520
=3.086

Current CPI (Jun. 2026) = 333.9520.

Teva Pharmaceutical Industries Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 5.037 241.428 6.967
201612 6.046 241.432 8.363
201703 5.194 243.801 7.115
201706 5.006 244.955 6.825
201709 4.634 246.819 6.270
201712 4.047 246.524 5.482
201803 4.027 249.554 5.389
201806 3.953 251.989 5.239
201809 3.813 252.439 5.044
201812 3.393 251.233 4.510
201903 3.367 254.202 4.423
201906 3.384 256.143 4.412
201909 3.403 256.759 4.426
201912 3.685 256.974 4.789
202003 3.598 258.115 4.655
202006 3.124 257.797 4.047
202009 3.081 260.280 3.953
202012 3.342 260.474 4.285
202103 3.022 264.877 3.810
202106 2.926 271.696 3.596
202109 2.978 274.310 3.625
202112 3.293 278.802 3.944
202203 3.003 287.504 3.488
202206 3.226 296.311 3.636
202209 3.245 296.808 3.651
202212 3.293 296.797 3.705
202303 3.068 301.836 3.394
202306 3.195 305.109 3.497
202309 3.178 307.789 3.448
202312 3.652 306.746 3.976
202403 3.129 312.332 3.346
202406 3.414 314.175 3.629
202409 3.445 315.301 3.649
202412 3.561 315.605 3.768
202503 3.105 319.799 3.242
202506 3.119 322.561 3.229
202509 3.279 324.800 3.371
202512 3.433 324.054 3.538
202603 2.921 330.213 2.954
202606 3.086 333.952 3.086

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €17.53 mean?
Teva Pharmaceutical Industries (FRA:TEV) has a Cyclically Adjusted Revenue per Share of €17.53 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Teva Pharmaceutical Industries and its competitors.
Is Teva Pharmaceutical Industries' Cyclically Adjusted Revenue per Share too high?
Teva Pharmaceutical Industries' current Cyclically Adjusted Revenue per Share is €17.53. Overall, Teva Pharmaceutical Industries has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Teva Pharmaceutical Industries' Cyclically Adjusted Revenue per Share of €17.53 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current Cyclically Adjusted Revenue per Share is €17.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (FRA:TEV) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.50, compared to a current price of €30.00 — trading 71.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €17.53. Teva Pharmaceutical Industries' overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Teva Pharmaceutical Industries (FRA:TEV), the current Cyclically Adjusted Revenue per Share is €17.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (FRA:TEV) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of €30.00 is trading 71.4% above its estimated GF Value™ of €17.50. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for FRA:TEV:

  • Cyclically Adjusted Revenue per Share: €17.53
  • GF Value™: €17.50 vs. price of €30.00 (71.4% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the FRA:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
56GF Score

Get the complete analysis for FRA:TEV

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.00
Price
€17.50
GF Value